Focus on maintenance therapy in non-small-cell lung cancer.

Abstract

Future OncologyVol. 11, No. 2 EditorialFocus on maintenance therapy in non-small-cell lung cancerAlfredo TartaroneAlfredo Tartarone*Department of Onco-Hematology, Unit of Medical Oncology, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (PZ), Italy; E-mail Address: tarta1@virgilio.itSearch for more papers by this authorPublished Online:16 Jan 2015https://doi.org/10.2217/fon.14.211AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: maintenance therapynon-small-cell lung cancerpemetrexedReferences1 Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non squamous non small cell lung cancer (PARAMOUNT): a double-bind Phase 3 randomised controlled trial. Lancet Oncol. 13, 247–255 (2012).Crossref, Medline, CAS, Google Scholar2 Gridelli C, de Marinis F, Pujol JL et al. Safety, resource use and quality of life in PARAMOUNT: a Phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin in advanced nonsquamous non small cell lung cancer. J. Thorac. Oncol. 7, 1713–1721 (2012).Crossref, Medline, CAS, Google Scholar3 Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).Crossref, Medline, CAS, Google Scholar4 Zinner R, Ross H, Weaver R et al. Randomized open-label Phase III study study of pemetrexed plus carboplatin (PEMC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous non small cell lung cancer (NSCLC). ASCO Meeting Abstracts 31, LBA8003 (2013).Google Scholar5 Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non small cell lung cancer. J. Clin. Oncol. 27, 591–598 (2009).Crossref, Medline, CAS, Google Scholar6 Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non small cell lung cancer: a randomized double-blind Phase 3 study. Lancet 374, 1432–1440 (2009).Crossref, Medline, CAS, Google Scholar7 Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non small cell lung cancer: a multicenter, randomised, placebo-controlled Phase III study. Lancet Oncol. 11, 521–529 (2010).Crossref, Medline, CAS, Google Scholar8 Johnson BE, Kabbinavar F, Fehrenbacher L et al. ATLAS: randomized, double-blind, placebo controlled, Phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non small cell lung cancer. J. Clin. Oncol. 31, 3926–3934 (2013).Crossref, Medline, CAS, Google Scholar9 Barlesi F, Scherpereel A, Rittmeyer A et al. Randomized Phase III trial of maintenance bevacizumab with or without pemetrexed after first line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non small cell lung cancer: AVAPERL (MO22089). J. Clin. Oncol. 31, 3004–3011 (2013).Crossref, Medline, CAS, Google Scholar10 Barlesi F, Scherpereel A, Gorbunova V et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non small cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized Phase III trial. Ann. Oncol. 25, 1044–1052 (2014).Crossref, Medline, CAS, Google Scholar11 Patel JD, Socinski MA, Garon EB et al. PointBreak: a randomized Phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non small cell lung cancer. J. Clin. Oncol. 31, 3004–3011 (2013).Crossref, Medline, Google Scholar12 Gridelli C, Bennouna J, de Castro J et al. Randomized Phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non small cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin. Lung Cancer 12, 407–411 (2011).Crossref, Medline, CAS, Google Scholar13 Besse b, Adjei A, Bass P et al. 2nd ESMO Consensus Conference on lung cancer: non small cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann. Oncol. 25, 1475–1484 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 11, No. 2 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 113 times History Published online 16 January 2015 Published in print January 2015 Information© Future Medicine LtdKeywordsmaintenance therapynon-small-cell lung cancerpemetrexedFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.No writing assistance was utilized in the production of this manuscript.PDF download